Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib

Key facts

Sponsor

Sunnybrook Health Sciences Centre

Principal Investigator

Georg A. Bjarnason, MD, FRCPC

Toronto Sunnybrook Regional Cancer Centre

Intervention

Stereotactic radiotherapy(radiation)

Enrollment

38 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2021

Study locations (12)

• Tom Baker Cancer Centre, Calgary, Alberta, Canada
• Cross Cancer Institute, Edmonton, Alberta, Canada
• BC Cancer Agency, Vancouver, British Columbia, Canada
• Manitoba CancerCare Institute, Winnipeg, Manitoba, Canada
• QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
• Juravinski Cancer Centre, Hamilton, Ontario, Canada
• London Health Sciences Centre, London, Ontario, Canada
• Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
• Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
• Princess Margaret Hospital, Toronto, Ontario, Canada
• McGill University Health Centre, Montreal, Quebec, Canada
• Jewish General Hospital, Montreal, Quebec, Canada

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →